<DOC>
	<DOCNO>NCT01153828</DOCNO>
	<brief_summary>Retapamulin , topical pleuromutilin antibiotic , first new class topical antibiotic approve human use . In European Union ( EU ) , retapamulin approve treatment impetigo secondarily-infected traumatic lesion person nine month age . This study design examine retapamulin use pediatric population less nine month age . We conduct five-year assessment prescription retapamulin use General Practice Research Database . For year reporting , observed frequency prescription retapamulin , without same-day co-prescriptions topical mupirocin fusidic acid , identify . The five-year reporting period include five year distinct , non-overlapping , non-cumulative prescription use first exposure retapamulin , without same-day co-prescription topical mupirocin fusidic acid .</brief_summary>
	<brief_title>EU PV Retapamulin-Prescribing</brief_title>
	<detailed_description />
	<mesh_term>Impetigo</mesh_term>
	<mesh_term>Mupirocin</mesh_term>
	<mesh_term>Fusidic Acid</mesh_term>
	<criteria>The study population consist register `` research standard '' patient GPRD , evaluate annually five year . For year observation , denominator person patient register least one month prior calendar year . Hence , fiveyear reporting period distinct , nonoverlapping , noncumulative prescription use categorize person date birth ( mm/dd/year ) . Enrollment GPRD le one month duration .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Altargo</keyword>
	<keyword>Bactroban</keyword>
	<keyword>Fucidin</keyword>
	<keyword>Fusidic acid</keyword>
	<keyword>Mupirocin</keyword>
	<keyword>topical</keyword>
	<keyword>Retapamulin</keyword>
	<keyword>United Kingdom</keyword>
</DOC>